Thursday, October 15, 2026
ExploreSearch
Finance Via News
Source trace. Via News points to the documents behind its reporting and shows what we drew from each — so you can check any claim. How we source
Press releaseGlobeNewswire· January 26, 2026

Projet d’offre publique d’achat de EP Group sur Fnac Darty au prix de 36€ par action, en numéraire

View original at globenewswire.com
Projet d’offre publique d’achat de EP Group sur Fnac Darty au prix de 36€ par action, en numéraire LA DIFFUSION, LA PUBLICATION OU LA DISTRIBUTION DE CE COMMUNIQUÉ DE PRESSE, EN TOUT OU EN PARTIE, DIRECTEMENT OU INDIRECTEMENT, N'EST PAS AUTORISÉE AUX ÉTATS-UNIS, EN AUSTRALIE, AU CANADA, AU JAPON OU DANS TOUT AUTRE PAYS…
Opening lines of the source · GlobeNewswire · short snapshot — read the full document at the original

What we drew from this source

The claims Via News extracted from this document. We point to the source; we don't replace it.

  • EP Group intends to continue the main strategic orientations implemented by the Company and its management team as presented in the Beyond everyday strategic plan

    80% confidence

  • With EP Group, the Company's main shareholder since 2023 via Vesa Equity Investment, Fnac Darty has built a relationship of trust that enabled the transformative acquisition of Unieuro

    80% confidence

  • The tender offer project demonstrates renewed support for the Beyond everyday plan and longer-term strategy

    80% confidence

  • The Board of Directors unanimously welcomed this tender offer project from the Group's main shareholder

    80% confidence

  • EP Group does not intend to modify the dividend policy of the Company

    80% confidence

  • EP Group does not intend to request implementation of a squeeze-out procedure following the offer

    80% confidence

  • EP Group intends to maintain the management team, maintain the headquarters in France, and modify the composition of the Board of Directors after the offer to reflect the new shareholder structure

    80% confidence

Cited in these Via News reports

What we know · the intelligence behind this page
Live from the substrate
What we're seeing
Q4 2026 Clinical Catalyst Season: Big-Pharma Data Flow, Regulatory Milestones, and a Thin AI-Drug Fringe
October 2026 conferences (EASD, IGCS, NACFC, HFSA) are producing a dense run of late-stage readouts from Novo Nordisk, Lilly, Roche, Bayer, Vertex and Galderma. Regulatory milestones are scheduled behind them: the ivonescimab BLA PDUFA date on 2026-11-14, FDA acceptance of Roche's vamikibart BLA, and Scholar Rock's EMA resubmission. The AI-and-finance angle is peripheral. It consists of the AI-designed drug Rentosertib and QAIAx, a speculative microcap whose trial claims (the QIII pilot, anticipated 2027-01-01, and a patent update) are forecasts and filings rather than data, so they warrant skepticism.
Our read on the data ›
Signals we're tracking
EPKINLY Regulatory-Clinical Success Cascade
High probability of expanded label indications, additional combination approvals, and competitive positioning strength in follicular lymphoma market. Predicts positive commercial uptake and potential accelerated review for related indications.
Patterns we're watching ›
Where sources disagree
ING Group
Both facts record the same metric (shares_outstanding) for ING Group at the identical observation date (2025-12-31). FACT A states 2,902,437,688 shares; FACT B states 2,902 million shares (2,902,000,000). The difference is 437,688 shares (~0.015%). This is a genuine value conflict, though the discrepancy appears to result from FACT B rounding to the nearest million while FACT A provides the precise count.
We flag conflicts openly ›
Recently verified
✓ Checked against the original source
4,986
facts traced to their source — and we flag the ones that don't hold up.
101 entities tracked4,986 facts checked against source5,375 source documents archived
Query this data → isubstrate.com